JP5764823B2 - Wdrpuhエピトープペプチドおよびそれを含むワクチン - Google Patents

Wdrpuhエピトープペプチドおよびそれを含むワクチン Download PDF

Info

Publication number
JP5764823B2
JP5764823B2 JP2011524084A JP2011524084A JP5764823B2 JP 5764823 B2 JP5764823 B2 JP 5764823B2 JP 2011524084 A JP2011524084 A JP 2011524084A JP 2011524084 A JP2011524084 A JP 2011524084A JP 5764823 B2 JP5764823 B2 JP 5764823B2
Authority
JP
Japan
Prior art keywords
peptide
wdrpuh
ctl
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011524084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510794A (ja
JP2012510794A5 (cg-RX-API-DMAC7.html
Inventor
卓也 角田
卓也 角田
龍司 大沢
龍司 大沢
祥子 吉村
祥子 吉村
朝久 渡辺
朝久 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2012510794A publication Critical patent/JP2012510794A/ja
Publication of JP2012510794A5 publication Critical patent/JP2012510794A5/ja
Application granted granted Critical
Publication of JP5764823B2 publication Critical patent/JP5764823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011524084A 2008-12-05 2009-12-03 Wdrpuhエピトープペプチドおよびそれを含むワクチン Active JP5764823B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20096208P 2008-12-05 2008-12-05
US61/200,962 2008-12-05
US20970409P 2009-03-09 2009-03-09
US61/209,704 2009-03-09
PCT/JP2009/006573 WO2010064430A1 (en) 2008-12-05 2009-12-03 Wdrpuh epitope peptides and vaccines containing the same

Publications (3)

Publication Number Publication Date
JP2012510794A JP2012510794A (ja) 2012-05-17
JP2012510794A5 JP2012510794A5 (cg-RX-API-DMAC7.html) 2013-01-24
JP5764823B2 true JP5764823B2 (ja) 2015-08-19

Family

ID=42233088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011524084A Active JP5764823B2 (ja) 2008-12-05 2009-12-03 Wdrpuhエピトープペプチドおよびそれを含むワクチン

Country Status (18)

Country Link
US (3) US8541546B2 (cg-RX-API-DMAC7.html)
EP (3) EP2370454A4 (cg-RX-API-DMAC7.html)
JP (1) JP5764823B2 (cg-RX-API-DMAC7.html)
KR (1) KR101705102B1 (cg-RX-API-DMAC7.html)
CN (2) CN102307891B (cg-RX-API-DMAC7.html)
AU (1) AU2009323523B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922844A2 (cg-RX-API-DMAC7.html)
CA (2) CA3031126C (cg-RX-API-DMAC7.html)
DK (1) DK3219720T3 (cg-RX-API-DMAC7.html)
ES (1) ES2913148T3 (cg-RX-API-DMAC7.html)
IL (2) IL212945B (cg-RX-API-DMAC7.html)
MX (1) MX2011005944A (cg-RX-API-DMAC7.html)
NZ (2) NZ593086A (cg-RX-API-DMAC7.html)
RU (1) RU2514386C2 (cg-RX-API-DMAC7.html)
SG (1) SG171977A1 (cg-RX-API-DMAC7.html)
TW (2) TWI539160B (cg-RX-API-DMAC7.html)
WO (1) WO2010064430A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104890B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ube2tペプチドおよびそれを含むワクチン

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
CN101613406A (zh) 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
WO2003104275A2 (en) 2002-06-06 2003-12-18 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
EP2267023B1 (en) * 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
EP2370454A4 (en) 2013-11-20
EP4047009A2 (en) 2022-08-24
CN102307891B (zh) 2015-02-04
KR20110099018A (ko) 2011-09-05
EP2370454A1 (en) 2011-10-05
EP4047009A3 (en) 2022-11-16
BRPI0922844A2 (pt) 2015-12-29
TW201510529A (zh) 2015-03-16
RU2011127429A (ru) 2013-01-10
IL228266A (en) 2016-09-29
CA2745408C (en) 2019-03-12
ZA201104890B (en) 2012-03-28
KR101705102B1 (ko) 2017-02-22
JP2012510794A (ja) 2012-05-17
US20110293645A1 (en) 2011-12-01
RU2514386C2 (ru) 2014-04-27
TWI500932B (zh) 2015-09-21
US8541546B2 (en) 2013-09-24
NZ605799A (en) 2014-03-28
AU2009323523B2 (en) 2016-08-11
US9745343B2 (en) 2017-08-29
CA2745408A1 (en) 2010-06-10
TW201027074A (en) 2010-07-16
US20130315942A1 (en) 2013-11-28
US9115207B2 (en) 2015-08-25
NZ593086A (en) 2013-02-22
CA3031126A1 (en) 2010-06-10
AU2009323523A1 (en) 2010-06-10
TWI539160B (zh) 2016-06-21
WO2010064430A1 (en) 2010-06-10
US20150315239A1 (en) 2015-11-05
EP3219720A3 (en) 2018-01-03
CN102307891A (zh) 2012-01-04
ES2913148T3 (es) 2022-05-31
EP3219720A2 (en) 2017-09-20
EP3219720B1 (en) 2022-03-09
CA3031126C (en) 2022-03-22
SG171977A1 (en) 2011-07-28
CN104650183B (zh) 2018-04-20
CN104650183A (zh) 2015-05-27
DK3219720T3 (da) 2022-05-09
IL212945B (en) 2018-03-29
MX2011005944A (es) 2011-07-28
IL212945A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
JP5640262B2 (ja) Cdca1エピトープペプチドおよびそれを含むワクチン
JP5728717B2 (ja) Foxm1ペプチドおよびそれを含むワクチン
JP2011523937A (ja) Iqgap3エピトープペプチドおよびそれを含むワクチン
JP5816918B2 (ja) Melkエピトープペプチドおよびそれを含むワクチン
JP5728716B2 (ja) C1orf59ペプチドおよびそれを含むワクチン
US9745343B2 (en) Method of inducing an immune response by administering WDRPUH epitope peptides
WO2010070877A1 (en) Elovl7 epitope peptides and vaccines containing the same
AU2010216980B2 (en) FOXM1 peptides and vaccines containing the same
HK1240953A1 (en) Wdrpuh epitope peptides and vaccines containing the same
HK1165460B (en) Foxm1 peptides and vaccines containing the same
HK1165460A (en) Foxm1 peptides and vaccines containing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150408

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150525

R150 Certificate of patent or registration of utility model

Ref document number: 5764823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250